Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 2/20 | 0.32 |
| ▸ | F9 | P00740 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33526044 | 0.92 | F9 (0.30) | KLKB1F9 | |
| SCHEMBL33525797 | 0.91 | BTK (0.34) | KLKB1F9 | |
| SCHEMBL33525757 | 0.88 | GPR119 (0.33) | — | |
| SCHEMBL33526073 | 0.86 | KRAS (0.32) | — | |
| SCHEMBL33525656 | 0.86 | KRAS (0.38) | — | |
| SCHEMBL33525582 | 0.85 | — | — | |
| SCHEMBL33525670 | 0.85 | — | — | |
| SCHEMBL33525606 | 0.85 | — | — | |
| SCHEMBL33526651 | 0.85 | — | — | |
| SCHEMBL33525646 | 0.82 | LMNA (0.32) | KLKB1F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | KLKB1 4750/4885F9 1769/4885F11 951/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KLKB1 4727/4885F9 1746/4885F11 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.